• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Patient Preference and Adherence >Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart? in patients with multiple sclerosis
【24h】

Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart? in patients with multiple sclerosis

机译：Rebismart ？对多发性硬化症患者依从性对皮下干扰素β-1a有效性的影响

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Adherence to disease-modifying drugs (DMDs) is one of the key factors for achieving optimal clinical outcomes. Rebismart? is an injection device for subcutaneous administration of interferon beta-1a (INF β-1a) that is also able to monitor adherence objectively. The aim of this study was to describe adherence to INF β-1a using the said electronic autoinjection device and to explore the relationship between adherence and relapses in a Spanish cohort. Methods: This is a retrospective observational study in which 110 Spanish patients self-administered INF β-1a subcutaneously using an electronic autoinjection device between June 2010 and June 2015. The primary end point was the percentage of adherence measured by Rebismart? to subcutaneous INF β-1a injections calculated as number of injections received in time period versus number of injections scheduled in time period. Other variables recorded were demographic and clinical data. Statistical analysis was performed using SPSS 19.0 software. Results: Median adherence for the total study period was 96.5% (interquartile range [IQR]: 91.1–99.1). Similar values were observed during the first 6?months: 98.7% (IQR: 91.3–100), and the last 6?months: 97.6% (IQR: 91.1–99.8). Median duration of treatment was 979?days (IQR: 613.8–1,266.8). During the entire treatment period, 77.3% of patients were relapse free and mean annualized relapse rate was 0.14 (standard deviation: 0.33). Increased adherence was associated with better clinical outcomes, leading to lower relapse risk (odds?ratio: 0.953; 95% confidence interval: 0.912–0.995). Specifically, every percentage unit increase in adherence resulted in a 4.7% decrease in relapse. Conclusion: Patients with multiple sclerosis who self-injected INF β-1a with Rebismart? had excellent adherence, correlating with a high proportion of relapse-free patients and very low annualized relapse rate.
机译：背景：坚持改变疾病的药物（DMD）是获得最佳临床结果的关键因素之一。 Rebismart ？是用于皮下注射干扰素β-1a（INFβ-1a）的注射装置，它也能够客观地监测依从性。这项研究的目的是描述使用所述电子自动注射装置对INFβ-1a的依从性，并探讨西班牙人群中依从性与复发之间的关系。方法：这是一项回顾性观察性研究，其中110名西班牙患者在2010年6月至2015年6月之间使用电子自动注射装置皮下注射INFβ-1a。主要终点是通过Rebismart ？< / sup>皮下INFβ-1a注射量的计算方法是：该时间段内接收的注射次数与该时间段内计划的注射次数。记录的其他变量是人口统计和临床数据。使用SPSS 19.0软件进行统计分析。结果：整个研究期间的中位依从率为96.5％（四分位间距[IQR]：91.1–99.1）。在最初的6个月中观察到了相似的值：98.7％（IQR：91.3–100），最近的6个月中：97.6％（IQR：91.1–99.8）。中位治疗时间为979天（IQR：613.8–1,266.8）。在整个治疗期间，77.3％的患者无复发，年平均复发率为0.14（标准差：0.33）。依从性增加与更好的临床结果相关，从而降低了复发风险（比值：0.953; 95％置信区间：0.912-0.995）。具体来说，依从性每提高一个百分比，导致复发率降低4.7％。结论：多发性硬化症患者使用Rebismart ？自行注射INFβ-1a的依从性良好，与无复发患者的比例较高且年复发率极低有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号